An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumab

References

• Keating M J, O'Brien S, Kontoyiannis D, Plunkett W, Koller C, Beran M, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002; 43: 1755–1762
   PubMed Web of Science ®Google Scholar
• Osterborg A, Dyer M J, Bunjes D, Pangalis G A, Bastion Y, Catovsky D, Mellstedt H. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European study group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J Clin Oncol 1997; 15: 1567–1574
   PubMed Web of Science ®Google Scholar
• Keating M J, Flinn I, Jain V, Binnet J L, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (CAMPATH-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–3561
   PubMed Web of Science ®Google Scholar
• Rai K R, Freter C E, Mercier R J, Cooper M R, Mitchell B S, Stadtmauer E A, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received flludarabine. J Clin Oncol 2002; 20: 3891–3897
   PubMed Web of Science ®Google Scholar
• Faderl S, Coutrè C, Byrd J C, Dearden C, Denes A, Dyer M JS, et al. The evolving role of Alemtuzumab in management of patients with CLL. Leukemia 2005; 19: 2147–2152
   PubMed Web of Science ®Google Scholar
• Bowen A L, Zomas A, Emmett E, Matutes E, Dyer M J, Catowsky D. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukemia. Br J Haematol 1996; 93: 151–153
   PubMed Web of Science ®Google Scholar
• Montillo M, Cafro A M, Tedeschi A, Brando B, Oreste P, Veronese S, et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 2002; 87: 695–700
   PubMed Web of Science ®Google Scholar
• Lundin J, Kimby E, Bjjorkholm M, Broliden P A, Celsing F, Hjalmar V, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768–773
   PubMed Web of Science ®Google Scholar
• Osterborg A, Fassas A S, Anagnostopoulos A, Dyer M J, Catovsky D, Mellsteedt H. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukemia. Br J Haematol 1996; 93: 151–153
   PubMed Web of Science ®Google Scholar
• Keating M J, Coutrè S, Rai K, Osterborg A, Faderl S, Kennedy B, et al. Management guidelines for use of Alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymph 2004; 4: 220–227
   PubMedGoogle Scholar
• Montillo M, Tedeschi A, Miqueleiz S, Veronese S, Cairoli R, Intropido L, et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006; 24: 2337–2342
   PubMed Web of Science ®Google Scholar
• Rawstron A C, Kennedy B, Moreton P, Dickinson A J, Cullen M J, Richards S J, , et al. Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood 2004; 106: 2027–2031
   Web of Science ®Google Scholar
• Chakrabarti S, Mackinnon S, Chopra R, Kottaridis P D, Peggs K, O'Gorman P, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357–4363
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Avivi I, Mackinnon S, Ward K, Kottaridis P D, Osman H, et al. Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality. Br J Haematol 2002; 119: 1125–1132
   PubMed Web of Science ®Google Scholar
• Cheson B D, Bennett J M, Grever M, Kay N, Keating M J, O'Brien S, Rai K R. National Cancer Institute sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997
   PubMed Web of Science ®Google Scholar
• Leruez-Ville M, Ouachee M, Delarue R, Sauget A S, Blanche S, Buzyn A, Rouzioux C. Monitoring cytomegalovirus infection in adult and pediatric bone marrow transplant recipients by a real-time PCR assay performed with blood plasma. J Clin Microbiol 2003; 41: 2040–2046
   PubMed Web of Science ®Google Scholar
• Nguyen D D, Cao T M, Dugan K, Starcher S A, Fecther L, Coutre S E. Cytomegalovirus viremia during Campath-H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma 2002; 3: 105–110
   PubMedGoogle Scholar
• Nosari A, Molteni A. Risk of infections when using new therapeutic approaches for chronic lymphocytic leukemia. Haematologica 2003; 88(Suppl 17)43–49
   Google Scholar
• Laurenti L, Piccioni P, Cattani P, Cingolani A, Efremov D, Chiuslo P, et al. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica 2004; 89: 1248–1252
   PubMed Web of Science ®Google Scholar
• Ayala E, Greene J, Sandin R, Perkins J, Field T, Tate C, et al. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 37: 851–856
   PubMed Web of Science ®Google Scholar
• van der Heiden P L, Kalpoe J S, Barge R M, Willemze R, Kroes A C, Schippers E F. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant 2006; 37: 693–698
   PubMed Web of Science ®Google Scholar
• Mackus W JM, Frakking F NJ, Grummels A, Gamadia L E, de Bree G J, Hamann D, et al. Expansion of CMV-specific CD8+CD45RA+; CD27− Tcells in B-cell chronic lymphocytic leukemia. Blood 2003; 102: 1057–1063
   PubMed Web of Science ®Google Scholar